Literature DB >> 13288790

Blood coagulation in pregnancy: proconvertin and prothrombin, and the hypercoagulable state.

B ALEXANDER, L MEYERS, J KENNY, R GOLDSTEIN, V GUREWICH, L GRINSPOON.   

Abstract

Entities:  

Keywords:  BLOOD COAGULATION; PREGNANCY/blood in; PUERPERIUM/blood in

Mesh：

Substances：

Year:  1956        PMID： 13288790     DOI： 10.1056/NEJM195602232540803

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  7 in total

1.  THE EFFECT OF LANTHANIDES AND ACTINIDES ON BLOOD COAGULATION. II. ASSAY OF A NEW SERUM THROMBOPLASTIC FACTOR VULNERABLE TO THESE ELEMENTS AND ITS VARIATIONS IN HEALTH AND DISEASE.

Authors:  R COLMAN; B ALEXANDER
Journal:  J Clin Invest       Date:  1964-04       Impact factor: 14.808

2.  [Obstetrical shock, a pathogenetic problem].

Authors:  P WILLE
Journal:  Arch Gynakol       Date:  1960

3.  Reduction of factor VII coagulant activity (VIIC), a risk factor for ischaemic heart disease, by fixed dose warfarin: a double blind crossover study.

Authors:  L Poller; P K MacCallum; J M Thomson; W Kerns
Journal:  Br Heart J       Date:  1990-04

4.  [A study of clotting factors under labor. II. Factor XI, glas-contact-activation test, consumption of prothrombin. Inhibitor of tissue thromboplastin, thrombocytes].

Authors:  W W Stein; E Halberstadt; L Wüst; H J Rothe
Journal:  Arch Gynakol       Date:  1970

5.  Placental barrier to coagulation factors: its relevance to the coagulation defect at birth and to haemorrhage in the newborn.

Authors:  J F Cade; J Hirsh; M Martin
Journal:  Br Med J       Date:  1969-05-03

6.  The levels of the plasma coagulation factors after trauma and childbirth.

Authors:  E DAVIDSON; S TOMLIN
Journal:  J Clin Pathol       Date:  1963-03       Impact factor: 3.411

Review 7.  Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy.

Authors:  H G Shetty; A G Fennerty; P A Routledge
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.